Summary
Amgen Inc. reported solid financial results for the second quarter and first half of 2022. Total revenues grew modestly, driven by a 3% increase in product sales for both the quarter and the six-month period. This growth was primarily fueled by strong performance in key products like Prolia, Otezla, XGEVA, Repatha, and KYPROLIS, which experienced double-digit percentage increases in sales. Operating income saw a substantial increase of 58% for the six months ended June 30, 2022, largely due to the absence of a significant acquired in-process research and development (IPR&D) charge recorded in the prior year from the Five Prime acquisition. Diluted Earnings Per Share (EPS) also showed significant improvement, rising 41% for the six months. The company's balance sheet remains robust, though cash and cash equivalents decreased compared to the prior year-end, partly due to significant share repurchases. Amgen continued its commitment to returning capital to shareholders, repurchasing approximately $6.4 billion in stock and paying dividends during the first six months of the year. The company also announced a proposed acquisition of ChemoCentryx for approximately $4.0 billion, indicating a continued strategy of growth through business development. Despite positive operational performance, investors should note the ongoing significant U.S. Tax Court litigation concerning tax years 2010-2015, which could result in substantial additional tax liabilities if the IRS's position prevails. While Amgen believes its tax accruals are appropriate, this remains a notable risk factor.
Financial Highlights
54 data points| Revenue | $6.59B |
| Cost of Revenue | $1.51B |
| Gross Profit | $5.08B |
| SG&A Expenses | $1.33B |
| Operating Expenses | $4.42B |
| Operating Income | $2.18B |
| Interest Expense | $328.00M |
| Net Income | $1.32B |
| EPS (Basic) | $2.46 |
| EPS (Diluted) | $2.45 |
| Shares Outstanding (Basic) | 535.00M |
| Shares Outstanding (Diluted) | 537.00M |
Key Highlights
- 1Total revenues increased by 1% to $6.594 billion for the three months ended June 30, 2022, and by 3% to $12.832 billion for the six months ended June 30, 2022, compared to the prior year periods.
- 2Product sales grew by 3% to $6.281 billion for the three months and $12.012 billion for the six months ended June 30, 2022, driven by strong performances in key drugs like Prolia, Otezla, XGEVA, Repatha, and KYPROLIS.
- 3Operating income significantly increased by 58% to $4.676 billion for the six months ended June 30, 2022, primarily due to the absence of a $1.5 billion acquired IPR&D expense from the prior year.
- 4Diluted EPS rose by 41% to $5.13 for the six months ended June 30, 2022, reflecting improved profitability.
- 5Amgen repurchased $6.4 billion of its common stock and paid $2.1 billion in dividends during the first six months of 2022, demonstrating a strong commitment to returning capital to shareholders.
- 6The company announced a proposed acquisition of ChemoCentryx for approximately $4.0 billion, signaling continued investment in strategic growth opportunities.
- 7Significant ongoing U.S. Tax Court litigation related to tax years 2010-2015 presents a material risk, with potential for substantial additional tax liabilities.